This antitumor immune augmenting effect of the PIT combination with ICB has extensively been reported against numerous breast cancer TAAs, including CD44, HER‐2, and EGFR receptors (Table 1) [8, 62, 63, 65, 300, 301]. This evidence concerns the gene ERBB2 and breast cancer.